Advertisement


Smitha S. Krishnamurthi, MD, on Colorectal Cancer: Treatment Updates

NCCN 2022 Annual Conference

Advertisement

Smitha S. Krishnamurthi, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses prognostic assays for localized colon cancer, the potential clinical uses and current limitations of prognostic assays for stage II to III disease, and checkpoint inhibitor therapy for metastatic colorectal cancer.



Related Videos

Issues in Oncology
Survivorship

Maria Alma Rodriguez, MD, on Vaccinations for Patients With Cancer and Cancer Survivors

Maria Alma Rodriguez, MD, of The University of Texas MD Anderson Cancer Center, discusses the need for various types of vaccinations in patients with cancer, who are vulnerable to infection while under active treatment and whose immune deficits may persist long after treatment is finished. Dr. Rodriguez reviews new treatment guidelines and the steps oncology clinicians should take to ensure their patients are protected against infections.

Skin Cancer
Immunotherapy

Genevieve Boland, MD, PhD, on Advanced Melanoma: Best Management Practices

Genevieve Boland, MD, PhD, of Massachusetts General Hospital Cancer Center, discusses targeted treatments and immunotherapies and how they have dramatically changed the landscape in melanoma. Initially used in advanced disease, these agents are now being used in local or locoregional melanoma in the adjuvant and/or neoadjuvant settings. Dr. Boland also talks about the critical importance of multidisciplinary teams to integrate the latest recommendations for patient care.

Colorectal Cancer

Reid M. Ness, MD, MPH, on Colorectal Cancer: Updates in Screening Recommendations

Reid M. Ness, MD, MPH, of Vanderbilt-Ingram Cancer Center, discusses significant updates to the NCCN Clinical Practice Guidelines in Oncology for colorectal cancer screening: lowering the age from 50 to 45 for the initiation of average-risk screening for all combinations of race, ethnicity, and sex; and extending the surveillance interval from 5 to 7–10 years following the identification of one to two low-risk adenomas.

Prostate Cancer

Julio M. Pow-Sang, MD, on Nonmetastatic Prostate Cancer: Update on Best Management Practices

Julio M. Pow-Sang, MD, of Moffitt Cancer Center, discusses the treatment landscape for localized prostate cancer and its heterogeneity, the critical importance of stratifying risk to determining treatment options, and the continued improvement of therapy in the field.

Lymphoma

Ann S. LaCasce, MD, MMSc, on Relapsed/Refractory Indolent Follicular Lymphoma: Management Updates

Ann S. LaCasce, MD, MMSc, of Dana-Farber Cancer Institute, discusses the various agents available to treat patients with indolent B-cell lymphomas: lenalidomide plus rituximab, which has a superior progression-free survival profile compared with rituximab monotherapy; the PI3K inhibitors copanlisib and umbralisib, which have similar efficacy yet distinct side-effect profiles; tazemetostat, which is active in both EZH2-mutant and Warthin’s tumor disease; and CAR T-cell therapy, which shows early activity.

Advertisement

Advertisement




Advertisement